Erythropoietin (EPO) affords more potent cardioprotection by activation of distinct signaling to mitochondrial kinases compared with carbamylated EPO

Cardiovascular Drugs and Therapy

Volumn 24, Issue 5-6, 2010, Pages 401-408

  Sato, Takahiro ^a   Tanno, Masaya ^a   Miki, Takayuki ^a   Yano, Toshiyuki ^a   Sato, Tatsuya ^a   Shimamoto, Kazuaki ^a   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Erythropoietin; Infarct size; Mitochondria; Signal transduction

Indexed keywords

CARBAMYLATED ERYTHROPOIETIN; ERYTHROPOIETIN; GLYCOGEN SYNTHASE KINASE 3BETA; MITOCHONDRIAL ENZYME; PROTECTIVE AGENT; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TREATMENT FAILURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IMMUNOBLOTTING; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOTONIC AGENTS; ERYTHROPOIETIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOGEN SYNTHASE KINASE 3; MALE; MITOCHONDRIA; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PHOSPHORYLATION; PROTEIN KINASE C-EPSILON; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 79958182363     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-010-6265-5     Document Type: Article

References (41)

1. Joyeux-Faure M. Cellular protection by erythropoietin: new therapeutic implications? J Pharmacol Exp Ther. 2007;323:759-62.
2. Ruifrok WP, de Boer RA, Westenbrink BD, van Veldhuisen DJ, van Gilst WH. Erythropoietin in cardiac disease: new features of an old drug. Eur J Pharmacol. 2008;585:270-7.
3. Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA. The β chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood. 1997;90:1867-73. (Pubitemid 27377296)
4. Chin H, Wakao H, Miyajima A, Kamiyama R, Miyasaka N, Miura O. Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor β subunit (βIL3) and recruitment of Stat5 to possible Stat5-dokcing sites in βIL3. Blood. 1997;89:4327-36. (Pubitemid 27260240)
5. D'Andrea RJ, Gonda TJ. A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit. Exp Hematol. 2000;28:231-43.
6. Fiordaliso F, Chimenti S, Staszewsky L, BaiA, Carlo E, Cuccovillo I, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2005;102:2046-51. (Pubitemid 40262009)
7. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004;305:239-42. (Pubitemid 38886736)
8. Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood. 2010;115:4264-72.
9. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytome PC-12 cells. Cell Signal. 2007;19:634-45.
10. Kanellakis P, Pomilio K, Agrotis A, Gao X, Du XJ, Bobik A. Darbepoietin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor. Br J Pharmacol. 2010;160:2085-96.
11. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007;12:217-34. (Pubitemid 350176695)
12. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535-49. (Pubitemid 39071677)
13. Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, et al. Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol. 2007;43:564-70. (Pubitemid 47615050)
14. Ohori K, Miura T, Tanno M, Miki T, Sato T, Ishikawa S, et al. Ser9 phosphorylation of mitochondrial GSK-3beta is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis. Am J Physiol Heart Circ Physiol. 2008;295:H2079-86.
15. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, et al. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol. 2006;291:H748-55.
16. Kobayashi H, Miura T, Ishida H, Miki T, Tanno M, Yano T, et al. Limitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperfusion. Clin Exp Pharmacol Physiol. 2008;35:812-9. (Pubitemid 351725241)
17. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res. 2009;104:1240-52.
18. Miura T, Miki T. GSK-3beta, a therapeutic target for cardiomyocyte protection. Circ J. 2009;73:1184-92.
19. Miki T, Miura T, Tanno M, Nishihara M, Naitoh K, Sato T, et al. Impairment of cardioprotective PI3K-Akt signaling by post-infarct ventricular remodeling is compensated by an ERK-mediated pathway. Basic Res Cardiol. 2007;102:163-70. (Pubitemid 46189957)
20. Miura T, Yano T, Naitoh K, Nishihara M, Miki T, Tanno M, et al. Delta-opioid receptor activation before ischemia reduces gap junction permeability in ischemic myocardium by PKC-epsilon-mediated phosphorylation of connexin 43. Am J Physiol Heart Circ Physiol. 2007;293:H1425-31.
21. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A. 2003;100:6741-6. (Pubitemid 36666650)
22. Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther. 2006;316:999-1005. (Pubitemid 43345271)
23. Xu X, Cao Z, Cao B, Li J, Guo L, Que L, et al. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery. 2009;146:506-14.
24. Ramirez R, Carracedo J, Nogueras S, Buendia P, Merino A, Cañadillas S, et al. Carbamylated darbepoetin derivative prevents endothelial progenitor cell damage with no effect on angiogenesis. J Mol Cell Cardiol. 2009;47:781-8.
25. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288:H971-6.
26. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol. 2004;44:1103-10. (Pubitemid 39165147)
27. Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. Heart Fail Rev. 2007;12:181-8. (Pubitemid 350176691)
28. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol. 2009;104:189-202.
29. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation. 2008;117:2761-8. (Pubitemid 351770456)
30. Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarctsize in themyocardiumin vitro. Cardiovasc Drugs Ther. 2005;19:333-6. (Pubitemid 43029818)
31. Baker JE, Kozik D, Hsu AK, Fu X, Tweddell JS, Gross GJ. Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms. J Cardiovasc Pharmacol. 2007;49:337-45.
32. Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, et al. Mitochondrial PKCε and MAPK form signaling modules in the murine heart. Enhanced mitochondrial PKCε-MAPK interactions and differential MAPK activation in PKCε-induced cardioprotection. Circ Res. 2002;90:390-7.
33. Baines CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL, et al. Protein kinase Cε interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res. 2003;92:873-80. (Pubitemid 36542528)
34. Rasola A, Sciacovelli M, Chiara F, Pantic B, Brusilow WS, Bernardi P. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci. 2010;107:726-31.
35. Miki T, Miura T, Hotta H, Tanno M, Yano T, Sato T, et al. Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition. Diabetes. 2009;58:2863-72.
36. Zorov DB, Juhaszova M, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res. 2009;83:213-25.
37. Sun L, Shurkair S, Naik TJ, Moazed F, Ardehali H. Glucose phophorylation and mitochondrial binding are required for the protective effects of hexokinases I and II. Mol Cell Biol. 2008;28:1007-17. (Pubitemid 351160057)
38. Costa ADT, Garlid KD. Intramitochondrial signaling: interactions among mitoKATP, PKCε, ROS, and MPT. Am J Physiol Heart Circ Physiol. 2008;295:H879-82.
39. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV, et al. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res. 2005;97:329-36. (Pubitemid 41216137)
40. Nishino Y, Webb IG, Davidson SM, Ahmed AI, Clark JE, Jacquet S, et al. Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ Res. 2008;103:307-14.
41. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, et al. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res. 2009;104:15-8.